EU begins review of Bavarian Nordic’s vaccine for monkeypox

The European UnionThe Food and Drug Administration said on Tuesday that it had begun a review to expand the use of the Bavarian Nordic smallpox vaccine to prevent monkeypox.
Danish biotech’s Imvanex vaccine is approved for smallpox in Europe, but has been offered for off-label use to treat cases of monkeypox.
More than 3,400 cases of monkeypox have been confirmed and one death has been reported World Health Organization until last week, with the majority of them coming from Europe.
Bavarian Nordic has been vaccinated against both smallpox and monkeypox in USAwhere it’s called Jynneos.
The EU’s decision to initiate a review is based on results from laboratory studies showing that the vaccine triggers the production of antibodies that target monkeypox virus, European Health Agency speak.
The regulator also recommended importing vaccines from the United States to supplement tight supplies in Europe as infection rates rise across the bloc.
Earlier in June, the European Union signed an agreement with Bavarian Nordic to supply about 110,000 doses of monkeypox vaccine.

Source link


Kig News: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button